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Oncoprotein activationWe have recently demonstrated that Taspase1-mediated cleavage of the AF4–MLL oncoprotein results in the
formation of a stable multiprotein complex which forms the key event for the onset of acute proB leukemia in
mice. Therefore, Taspase1 represents a conditional oncoprotein in the context of t(4;11) leukemia. In this report,
we used site-directed mutagenesis to unravel the molecular events by which Taspase1 becomes sequentially
activated. Monomeric pro-enzymes form dimers which are autocatalytically processed into the enzymatically
active form of Taspase1 (αββα). The active enzyme cleaves only very few target proteins, e.g., MLL, MLL4 and
TFIIA at their corresponding consensus cleavage sites (CSTasp1) as well as AF4–MLL in the case of leukemogenic
translocation. This knowledge was translated into the design of a dominant-negative mutant of Taspase1
(dnTASP1). As expected, simultaneous expression of the leukemogenic AF4–MLL and dnTASP1 causes the disap-
pearance of the leukemogenic oncoprotein, because the uncleaved AF4–MLL protein (328 kDa) is subject to
proteasomal degradation, while the cleaved AF4–MLL forms a stable oncogenic multi-protein complex with a
very long half-life.Moreover, coexpression of dnTASP1with a BFP-CSTasp1-GFP FRET biosensor effectively inhibits
cleavage. The impact of our ﬁndings on future drug development and potential treatment options for t(4;11)
leukemia will be discussed.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The chromosomal translocation t(4;11) results from an illegitimate
recombination event that involves both the MLL/KMT2A (11q23)
and AF4/AFF1 (4q21) gene. Such genetic aberrations are frequently
diagnosed in early childhood and pediatric acute leukemia patients
(Meyer et al., 2009). Despite all the improvements over the past
decades, the current treatment regimen for these patients — mainly
if the disease occurs within the ﬁrst year of life — results in poor out-
come. Genetic rearrangements of MLL and AF4 are mostly caused by
balanced chromosomal translocations, resulting in the creation of two
fusion genes, MLL–AF4 and AF4–MLL, respectively. Both fusion alleles
are detected in about 80% of t(4;11) leukemia patients, while 20% of
t(4;11) leukemia patients exhibit complex rearrangements with three
or more fusion genes (Kowarz et al., 2007). Moreover, it was recently
demonstrated that both reciprocal t(4;11) fusion proteins give rise to
leukemia development in the murine system: (1) expression of anBiology, University of Frankfurt,
(R. Marschalek).
. This is an open access article underMll–AF4 fusion protein in a transgenic knock-in mouse strain resulted
in the development of AML andALL (Krivtsov et al., 2008); (2) retroviral
expression of theAF4–MLL fusion protein alone resulted in the develop-
ment of proB ALL in mice (Bursen et al., 2010). Noteworthy, a recent
study has demonstrated that MLL–AF4 causes an increased expression
of RUNX1 which promotes the onset of leukemia for the case of AF4–
MLL translocation (Wilkinson et al., 2013).
To become oncogenic AF4–MLL requires a prior endoproteolytic
cleavage mediated by Taspase1 (Bursen et al., 2004). Taspase1 was
discovered as a sequence-speciﬁc endopeptidase that hydrolyzes the
MLL protein at two cleavage sites, CS1 and CS2, both localized within
the C-terminal portion of the MLL protein. Enzymatic hydrolysis of
MLL occurs between amino acid positions 2666/2667 and 2718/2719
(Hsieh et al., 2003a,b). Subsequently, the resulting MLL protein frag-
ments (p320N and p180C) dimerize and form a high molecular weight
complex. This MLL multi-protein complex carries out important epige-
netic functions (H3K4me3; H4K16Ac; HAc) that are directly linked to
transcriptional maintenance (Nakamura et al., 2002; Yokoyama et al.,
2004; Dou et al., 2005). All of these functions are carried out in a
transcription factor dependent fashion (MENIN1, LEDGF and c-MYB)
(Yokoyama et al., 2004; Yokoyama and Cleary, 2008; Jin et al., 2010),the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2005).Moreover, theMLL complex regulates developmental and differ-
entiation processes, and is required for the normal development of the
hematopoietic system (Ono et al., 2005; Jude et al., 2007; McMahon
et al., 2007; Gan et al., 2010).
Taspase1 represents a highly unique enzyme that has co-evolved
in vertebrates and invertebrates together with proteins of the
Trithorax/MLL family. The crystal structure of Taspase1 has already
been revealed (PDB-ID: 2A8I, 2A8J, 2A8J) (Khan et al., 2005). According
to these structures, twomonomeric Taspase1 proenzymes (p50) form a
homodimer (p50/p50) that are subsequently processed into two α-
(amino acids 1–233; p28) and two β-subunits (234–420; p22), both
of which remain stably associated (αββα). Importantly, the β-subunit
carries the N-terminal threonine-234 residue (T234), which represents
the catalytic center (Khan et al., 2005). Thus, a Taspase1 homodimer
exhibits two catalytic centers that are oriented in an angle of about
108° at opposing sides of the dimer. Both catalytic centers contain
a single chloride ion that is part of an intrinsic regulatory mechanism
and inhibits Taspase1 at physiological sodium chloride concentrations
(IC50 ~ 25mMNaCl) (Khan et al., 2005;Michalska et al., 2006). The target
consensus sequence hydrolyzed by Taspase1 is Q3[F,I,L,V]2D1|G1'X2'X3'D4',
but only MLL, MLL4 and TFIIA as well as the oncogenic AF4–MLL fusion
protein are conﬁrmed substrates (Bursen et al., 2004; Hsieh et al.,
2003b; Zhou et al., 2006).
For the AF4–MLL fusion protein the Taspase1-induced protein frag-
ments (p178N and p180C) heterodimerize via speciﬁc domains localized
in both protein fragments (FYRN and FYRC) (Yokoyama et al., 2002;
Hsieh et al., 2003a). After dimerization, a multi-protein complex is
formed that exerts strong oncogenic activities: a) ectopic activation of
P-TEFb kinase results in a hyperactivation of transcriptional elongation
processes, and b) co-bound histone methyltransferases cause ectopic
H3K4/H3K79 patterns which subsequently effectuate epigenetic dereg-
ulation in a genome-wide fashion (Benedikt et al., 2011). Without
the fragment dimerization both AF4–MLL fragments are subject to
proteasomal destruction (Pless et al., 2011).
Since Taspase1 processing of AF4–MLL is essential for its onco-
genic action, we investigated structure–function relationships of
human Taspase1. Using site-directed mutagenesis in combination
with functional experiments, we were able to demonstrate that
dimerization of two Taspase1 proenzymes is a prerequisite for the
autoproteolytic processing of Taspase1 into the necessary α- and
β-subunits. Based on our results, we designed a dominant-negative
Taspase1 variant that prevents the dimerization of AF4–MLL fragments
and induces the proteasomal degradation of the AF4–MLL. Moreover,
modiﬁed cells are unable to activate a FRET reporter. The relevance of
these ﬁndings for future cancer therapy will be discussed.
2. Methods
2.1. Modeling of Taspase1
Comparative protein (‘homology’) modeling of Taspase1 was per-
formed by examining available protein templates. Four different crystal-
lographic structures of Taspase1 were available from the Protein Data
Bank (PDB IDs: 2A8I, 2A8J, 2A8L, 2A8M) (Khan et al., 2005; Michalska
et al., 2006). PDB structure 2A8J (chain A) served as the template for
construction of a homologymodel of activated Taspase1. One structural
element (sequence positions 164–180) was modeled based on the
established structure of another glycosylasparaginase (PDB ID: 1P4K),
which has a sequence identity of 29% to Taspase1. The whole multi-
template modeling process was executed within the homology model-
ing software package MODELLER 9v3 (Eswar et al., 2006). The resulting
protein structural model was evaluated using PROCHECK (Laskowski
et al., 1993). The Ramachandran plot shows that 92.3% of all residues
are located within favored regions (Suppl. Fig. S2). Based on this obser-
vation we decided not to further minimize the model. The Taspase1model structure was duplicated and aligned to both chains of the com-
plex in PDB structure 2A8J using the ‘align’ function of the PyMOL soft-
ware package (Version 1.3, Schrödinger, LLC).
2.2. In Vitro Taspase1 Cleavage Assay
The cDNA of human Taspase1 was cloned into the pET22b expres-
sion plasmid and recombinantly expressed in E. coli strain BL21*
(Invitrogen, Darmstadt, Germany). An appropriate MLL substrate was
constructed by cloning a cDNA fragment of MLL comprising amino
acids 2614–2773 into the pGEX-5T expression vector. The resulting
GST–MLL fusion protein (p50) exhibits the CS1 (QVD·GADD) and CS2
(QLD·GVDD) sites for hydrolysis by Taspase1. Expression of the C-
terminal His-tagged Taspase1 protein and the N-terminal His-tagged
GST–MLL fusion protein (p50) was induced by adding 1 mM IPTG for
4 h, followed by Ni-NTA afﬁnity-puriﬁcation following the instructions
of the manufacturer (Sigma, Munich, Germany). For in vitro cleavage
assays, equal amounts of puriﬁed Taspase1 and GST–MLL substrate pro-
tein (~0.5 μg protein) were co-incubated in incubation buffer contain-
ing 40 mM Hepes/KOH pH 7.9, 10 mM KCl and 5 mM MgCl2 for
30 min at 37 °C. Enzyme, substrate and hydrolyzed products were sep-
arated on a 12% SDS-PAGE and Coommassie blue-stained for visual
inspection.
2.3. Site-directed Mutagenesis of Taspase1
Site-directed mutagenesis of Taspase1 and the GST–MLL substrate
protein was performed using a commercially available mutagenesis kit
(Agilent Technologies, Böblingen, Germany) in combination with spe-
ciﬁc oligonucleotides that are listed in Suppl. Table S1.
2.4. Testing the Dimerization Capacity of Different Taspase1 Mutants
Dimerization between Taspase1 variants was tested using a mam-
malian expression vector (pCDNA; Invitrogen, Darmstadt, Germany)
that contain Taspase1 (or its mutated variants) fused either to a C-
terminal Flag- or Myc-Tag (Hopp et al., 1988; Evan et al., 1985). Cor-
responding plasmids (Flag and Myc) containing either the mutated
Taspase1 variant or the combination of mutated Taspase1 variant
and wildtype Taspase1 were co-transfected into 293T cells for co-
immunoprecipitation experiments. Immunoprecipitation was always
performed using an anti-Flag Tag antibody (clone M2; Sigma, Munich,
Germany), while detection of dimerized Taspase1 was conﬁrmed in
Western blot experiments by using an anti-Myc Tag antibody (clone
9E10; Abcam, Cambridge, UK).
2.5. Cell Growth, Western Blot and Q-PCR Experiments
HEK293T were transfected with expression constructs for
wildtype Taspase1::Flag and the dnTASP1::Flag mutant variant in
conjunction with an AF4–MLL expression plasmid. SEM cells were
stably transfected with an inducible dnTasp or Luciferase expression
constructs. Transfected cells were selected with Puromycin and
nearly 100% pure cultures were used for all experiments, e.g., for
cell growth experiments. Total cell lysates were prepared and used
for Western blot experiments. For the detection of β-actin, the poly-
clonal antiserum #4967 (Cell Signaling, Schwalbach/TS, Germany)
was used. Similarly, stably transfected cells were used to prepare total
RNA that was subsequently used for quantitative PCR experiments
(n = 3). Appropriate primers for the quantiﬁcation of transcripts
derived from the HOXA1, HOXA3, HOXA7, HOAX9 and HOXA10 genes
were designed. The following primers were used: HOXA1·3 (5′-
acagaacttcagtgcgccttaca-3), HOXA1·5 (5′-gggagcgacaggcttcttg-3′),
HOXA7·3 (5′-agcttggaaattctgctcacttct-3′), HOXA7·5 (5′-tctgatgtca
tggccaaatttg-3′), HOXA9·3 (5′-gccggccttatggcattaa-3′), HOXA9·5 (5′-
cagggacaaagtgtgagtgtcaa-3′), HOXA10·3 (5′-aaagcctcgccggagaa-3′)
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tions were performed in triplicates and normalized against PDK1 using
the following primer set: PDK1·3 (5′-gagagtcgacttcaagttc-3′) and
PDK1·5 (5′-gtccttcaagaacagacat-3′).
2.6. In Vivo FRET Assay
The FRET biosensor reporter consists of a TagBFP/TagGFP FRET pair
separated by either of the 2 Taspase1 cleavage sites CS1 (AEGQVDGADD)
or CS2 (KISQLDGVDD), respectively. This FRET biosensor was stably
co-transfected with either wild-type Taspase1, dnTASP1 or empty vec-
tor (mock) by using a Sleeping Beauty vector system (Wächter et al.,
2014). All Taspase1 constructs or the mock vector co-expresses RFP
(dTomato) that was used for normalization. Transfections were carried
with the 2 different Taspase1 vectors or mock, the FRET biosensor
reporter vector and SB100X transposase plasmid (Mátés et al., 2009)
and then selected in the presence of either Puromycin (3 μg/ml; FRET
biosensor vector) and Blasticidin (10 μg/ml, Taspase1 vectors/mock).
Stable cell lines were obtained within 5–10 days. Biosensor cleavage
was measured via BFP quenching in the living cells. BFP ﬂuorescence
(Ex: 402 nm; Em: 457 nm) of 50,000 cells wasmeasuredwith a Thermo
Scientiﬁc Varioskan Flash plate reader (n = 12). The ﬂuorescence was
normalized to the dTomato ﬂuorescence (Ex: 554 nm; Em: 581 nm)
deriving from the Taspase1/mock vectors.
3. Results
3.1. Structural Modeling of Taspase1
The currently available crystal structure information on Taspase1
contains several unstructured regions that have not been resolved or
assigned (Khan et al., 2005). Amino acids 1–40, 206–229 and 352–362
are missing in PDB records 2A8I and 2A8J, respectively (Fig. 1, left
panel). The PDB structure 2A8J (chain A, active Taspase1) was chosen
to serve as the principal template for modeling of a full Taspase1 struc-
ture. The pair-wise alignment with the template contains a total of 66
gap positions. Missing residues belong to three continuous gaps. TheFig. 1. Computer-aided modeling of Taspase1 based on the available crystal structure. Left: cry
Right: modeling of missing amino acid residues 206–229 and 352–362, and of a structural elem
ture of Taspase1. Differences between the published crystal structure and the in silico remodele
ange spheres.lengths of the three gaps are two, 50, and 14 amino acids. Missing resi-
dues weremodeled based on three different protein structures. Based on
Taspase1 structure 2A8I (chain B) we modeled ten residues of the 14-
residue gap, while the remaining residues were modeled de novo. Using
the Taspase1 structure 2A8I (chain A, Taspase1 proenzyme) we recon-
structed the two-residue gap as well as 25 residues of the 50-residue
gap. Twenty-four of the 25 remaining gap residues were modeled
based on the established protein structure of glycosylasparaginase
(1P4K, chain C) (Qian et al., 2003), while one residue was modeled de
novo. As shown in Fig. 1 (right panel), the missing residues 206–229
and 352–362 form additional structural elements (shown in red). Se-
quence positions 164–180 were modeled based on the established
structure of another glycosylasparaginase (PDB ID: 1P4K); this resulted
in conformational changes of regions in positions 153–167 and
189–205 (also depicted in red).
3.2. Establishment of an In Vitro Taspase1 Hydrolysis Assay
Recombinant human Taspase1 and a GST–MLL substrate protein
(consisting of the E. coli GST protein fused to about 150 amino acids
deriving from the human MLL protein and containing the two cleavage
sites CS1 and CS2) were expressed and afﬁnity-puriﬁed using a C- and
N-terminal His-tag, respectively. In all Taspase1 preparations, the full-
length proenzyme (p50) co-puriﬁed along with equal amounts of the
autoproteolyzed protein fragments of Taspase1 (p28 & p22). This indi-
cated that the intrinsic Taspase1 autoproteolysis did not impair the
afﬁnity-puriﬁcation step. Protein preparations were subsequently used
for an in vitro hydrolysis assay. For each preparation, an SDS-PAGE
was performed to test the enzymatic activity of puriﬁed Taspase1. An
example is presented in Fig. 2, where decreasing amounts of a Taspase1
preparation were used in combination with a constant amount of the
substrate protein (ratios between Taspase1 and GST–MLL are 1:1 up
to 1:128). Cleavage of the substrate protein was most efﬁcient at a 1:1
ratio between Taspase1 and substrate protein. Therefore, all subsequent
in vitro proteolysis assays were performed with equimolar quantities of
recombinant Taspase1 and substrate protein. This assay was applied to
all Taspase1 mutants as outlined below.stal structure of human Taspase1 (Khan et al., 2005). The PDB-structure 2A8J is displayed.
ent formed by amino acid residues 164–180. This enabled us to modify the existing struc-
d Taspase1 structure are displayed in red. The catalytic T234 residues are displayed as or-
Fig. 2. In vitro Taspase1 enzyme assay. Left: afﬁnity-puriﬁed Taspase1 protein from E. coli. Due to autoproteolysis, the p50 full-length protein is hydrolyzed into the p28α- and the p22 β-
subunits. Middle: a dilution experiment of recombinant Taspase1 in the presence of constant amounts of the GST–MLL substrate protein.M: proteinmarker. First lane: approximately 1 μg
GST–MLL was coincubated with equimolar amounts of Taspase1 for 30 min at 37 °C. In subsequent lanes, the amount of Taspase1 was serially reduced by 2-fold. In the ﬁnal dilution
(1:128) no cleavage of the substrate protein could be observed. Right: scheme of the substrate protein that exhibits the cleavage sites CS1 and CS2, respectively; CS2 is the preferential
cleavage site in vitro (p38), while CS1 represents a minor cleavage site (p32).
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Mechanism
Previous reports from our laboratory demonstrated that the AF4–MLL
fusion protein requires Taspase1 to form a stable, oncogenic protein
complex (Benedikt et al., 2011). The AF4–MLL complex was shown
to be sufﬁcient to initiate the development of acute lymphoblastic
leukemia (ALL) in mice (Bursen et al., 2010). In the present study weFig. 3.Dissection of Taspase1 function by site-directedmutagenesis. A.Monomeric Taspase1 in
tom: surface view. Both the docking zone (DZ) and the docking head (DH) are indicated by circl
or substrate hydrolysis; residues shown in red: disabled dimerization, autoproteolysis or substr
displayed to show how their docking heads (DH) potentially bind to the corresponding dockinaddressed the following questions: (a) how important is the dimeriza-
tion process for Taspase1 activity?; (b) which amino acids are involved
in the autoproteolytic mechanism of the Taspase1 proenzyme?; and
(c) how can we interfere with the enzymatic activity of Taspase1?
We focused on several candidate amino acid positions by visual
inspection of the new model structure of Taspase1. First, amino acids
in the vicinity of the two amino acid residues D233 and T234 were
selected (Fig. 3A). The peptide bond between these residues needs tofront view (cartoon). B.Monomeric Taspase1 interaction interface. Top: cartoon view; bot-
es.Mutated amino acid residues shown in green: no effect on dimerization, autoproteolysis
ate hydrolysis. C. Proenzyme dimerization process; monomeric Taspase1 proenzymes are
g zones (DZ) of the opposing monomer.
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we chose Y61, H47, and S291 for site-directed mutagenesis because
they are localized near the D233/T234 dipeptide bond in the three-
dimensional space. Secondly, we realized that both Taspase1monomers
display a large interaction interface containing several candidate amino
acids (Fig. 3B). These are either able to form interactions by hydrogen
bonds or by stacking interactions. The following interface amino acid
residueswere selected: I160, H259, H281, R304, R299 and F332. Thirdly,
a ‘docking head’ became visible when each monomer was analyzed by
its own (Fig. 3C; DH = docking head, DZ = docking zone). Selected
amino acids are either localized in the ‘docking zone’ (E295 and R262)
or within the docking head (V142, L146, R159, L165, W173, and
H177). All these amino acids were subjected to site-directed mutagen-
esis. The resulting Taspase1 mutants were subsequently tested for:
(a) their ability to form dimers; (b) their autoproteolytic activity; and
(c) the ability to hydrolyze appropriate substrate protein.
As summarized in Fig. 3AB, mutations shown in green (Y61A, H47A,
R159A, H259A, H281A, R304A, and F332A) had neither an effect on
dimerization, autoproteolysis nor substrate cleavage. However, all
amino acid positions displayed in red interfered with the proper func-
tion of Taspase1. The mutants T234D and S291A had obviously no
autoproteolytic activity, and thus, were both unable to be converted
into an active enzyme. While the T234D mutation was already
published (Hsieh et al., 2003b), the importance of the S291 was not
previously appreciated. A visual inspection of the enzymatic centerFig. 4.Dimerization capability and in vitrohydrolysis activity of Taspase1mutants. A. Co-immun
experiments, Flag- and Myc-tagged Taspase1 variants were contransfected into HEK293T cells.
anti-Myc-Tag antibody. Lane 1: transfection of Taspase1-Myc and Taspase1-Flag; lane 2: tra
Taspase1-Myc and mutant Taspase-Flag; lane 4: mock-control experiments. Detection of p22 f
while autoproteolysis is inhibited. B. SDS-Page of wildtype and mutant Taspase1 variants. Reco
bination with the GST–MLL substrate protein (1-fold). Left lanes: protein size marker. Lane 1:
Taspase1 and GST–MLL substrate protein (CS1, CS2 and p50); lane 3: afﬁnity-puriﬁedmutant T
tein (only p50); lane 5: substrate GST–MLL protein (control; p50).suggested a potential mechanism for autoproteolysis, represented by
the presence of a catalytic triad (H47, S291, and D233; see Suppl.
Fig. S1A). However, the Taspase1 mutant H47A did not show any
impairment of the autoproteolytic process. Thus, from our set of
selected residues only S291 and D233 appear to be important for
the autoproteolytic process. We also tested for the possibility that an
N–O acyl shift mechanism is responsible for the autoproteolytic activity
of Taspase1 (Perler, 1998). Such a mechanism was identiﬁed for
another member of the threonine aspartase family member. Brieﬂy,
the glycosylasparaginase enzyme features a ‘scissile peptide bond’
between residue D151 and T152, which is autocatalytically hydro-
lyzed (Qian et al., 2003; Wang and Guo, 2010). The N–O acyl shift
mechanism should be enhanced by the presence of 500 mM hydroxyl-
amine, while the presence of 20 mM glycine should be inhibitory.
However, no differences in the amount of proenzyme (p50) or the
autoproteolytic peptides p28 and p22 were observed when compared
to untreated Taspase1 (see Suppl. Fig. S1D). Thus, we concluded that
autoproteolysis of Taspase1 apparently depends on S291 and D233, and
not on a ‘scissile peptide bond’ as described for glycosylasparaginase.
Scissile peptide bonds are normally characterized by a torsionally
deformed amide (Wang and Guo, 2010), which is neither visible in
the crystal structure nor in the new model of Taspase1.
Several othermutated amino acids— predominantly localized in the
dimerization interface — had a profound effect on the function of
Taspase1 (Fig. 3AB). Mutants R262A, E295A and R299E were all ableoprecipitation experiments of Flag- andMyc-tagged Taspase1 expression constructs. For all
After immunoprecipitation with anti-Flag-Tag antibody, all precipitates were probedwith
nsfection of mutated Taspase1-Myc and mutated Taspase-Flag; lane 3: transfection of
ragment: dimerization and autoproteolysis occurs; detection of p50: dimerization occurs,
mbinant Taspase1 was loaded either alone (in a 10-fold higher concentration) or in com-
afﬁnity-puriﬁed wildtype Taspase1 (p22, p28 and p50); lane 2: afﬁnity-puriﬁed wildtype
aspase1 (only p50); lane 4: afﬁnity-puriﬁedmutant Taspase1 and GST–MLL substrate pro-
391S. Sabiani et al. / EBioMedicine 2 (2015) 386–395to dimerize, but the process of autoproteolysis and substrate hydrolysis
was completely blocked (Fig. 4B). An exception was I160E, because this
particular mutation was still able to dimerize, but autoproteolysis
(Fig. 4A) and substrate hydrolysis was reduced (Fig. 4B). These
data indicated that certain amino acid positions in the ‘docking
zone’, e.g., R299, E295 and R262, are important for triggering the
autoproteolytic activity of Taspase1. In addition, the I160E mutation
indicated that also the ‘docking head’ of the opposing monomer has
relevance for this process. Both mutation clusters indicated for the ﬁrst
time, that the dimerization process of inactive Taspase1monomers is of
importance for the generation of enzymatically active Taspase1 dimers.
Another important ‘docking head’mutationwas theW173A Taspase1
mutant. This mutant was unable to form a homodimer, while mixing a
wildtype with the W173A mutant still allowed dimerization, although
to a much lesser extent (Fig. 4A). First, we assumed that the side-
chain of W173 is able to form an arene–arene interaction with the
H259 of the opposing Taspase1 monomer. However, the H259A muta-
tion displayed no such effect. Then, the amino acid positions H177,
L146, L165 and V142 were mutated into alanines. We tested various
single and double mutants (Fig. 5A). The results of these experiments
suggest that both L146 and L165 form a hydrophobic pocket for the
W173 residue, while H177 presumably stabilizes the position of the
W173 residue (Fig. 5B). Together these interactions may help to
stabilize a distinct three-dimensional conformation of the ‘docking
head’ in order to perform a ‘dock and click’mechanism with an oppos-
ing Taspase1 monomer. As summarized in Fig. 5C, neither the W173A,
the L146A/L165A nor the L146A/H177A mutants were able to form
stable docking heads. As a consequence, none of these 3 mutants was
able to dimerize. The V142A mutation served as a control and was not
expected to have an effect on the docking head structure. In
fact, this mutant did not impair the dimerization of Taspase1.Fig. 5.Mutational analysis of the docking head. The W173A mutant of Taspase1 was shown to
acids in the vicinity were mutated to alanines. A. Mutant Taspase1 variants were tested for th
experiment see Fig. 4B. B. Wildtype Taspase1 docking head. Left: cartoon view with spheric vie
between the tested amino acids. C.Mutant Taspase1 docking heads.W173A, L146A/L165A or L1
ization deﬁciency.Noteworthy, when the ‘docking head’ binds to its cognate docking
zone in an opposing Taspase1 monomer, the most important amino
acids affected by the dimerization process are again R262 and E295
(see below).
3.4. Dimerization is the Key Event to Activate an Intrinsic, Serine Protease-
like Activation Mechanism
These results motivated us to inspect the docking zone of
Taspase1 in more detail. When Taspase1 monomers bind to each
other, both ‘docking heads’ bind near the catalytic center of the oppos-
ing monomer (docking zone). An example of a single ‘docking zone’
(blue) is displayed in Fig. 6. We propose that binding of the ‘docking
head’ (green) leads to small changes in the opposing loop structure,
resulting in a movement of R262 towards E295. E295 — normally
attracted by the positive charge of R299 — would then move into the
direction of the positively charged R262. Since E295 is directly linked
to Ser291, this tiny movement of E295 may allow the correct position-
ing of S291 to initiate the essential autoproteolytic cleavage. Cleavage
of the D233–T234 peptide bondwould then activate the reactive center
of Taspase1, which in turnwould then allow substrate binding, and sub-
sequently, the hydrolysis of bound substrate protein.
This proposed activation mechanism for Taspase1 proenzymes is
supported by different experimental results: (a) we hypothesized that
an R262A mutation should disable any movement of E295 towards
R262, because of the missing positive charge. In fact, this particular
mutation displayed no Taspase1 activity at all, while dimerization was
not effected (Fig. 4AB); (b) similarly, an E295A mutation should also
disable the movement of E295 towards R262, due the missing negative
charge. Again, this single point mutation abolished any Taspase1
activity (Fig. 4AB); (c) ﬁnally, we hypothesized that a C163E mutationbe dimerization deﬁcient. In order to understand the function of W173, additional amino
eir ability to dimerize and to hydrolyze the GST–MLL substrate protein. For details of the
w of all tested amino acids. Right: docking head in cartoon view with indicated distances
46A/H177Amutantswere unable to dimerize. The control, V142A, did not display a dimer-
Fig. 6.Hypothetical mechanism of Taspase1 activation. Amino acids T286–T300 and G230–Q265 of Taspase1 represent the docking zone (blue colored). From the second Taspase1mono-
mer, only the docking head— represented by amino acids N138–H177— is displayed (green colored). Important amino acid residues are indicated by a combination of a single letter and a
number. Upon dimerization, the docking head binds to the docking zone. This causes a conformational change which enables R262 to attract residue E295. Subsequently, a tiny shift of
E295 towards R262 causes the correct placement of S291, which then executes the autoproteolytic step (cleavage of peptide bond D233/T234). All distances are displayed in Angstrom.
Inset: the consequences of the important C163Emutation are displayed. Upon dimerization with another Taspase1monomer, the necessarymovement of E295 towards R262 is presum-
ably blocked due to a clash of negative charges.
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E295 upon dimerization (see inset of Fig. 6). As a matter of fact, the
C163E mutant was still able to dimerize (Fig. 4A), but completely
blocked the step of autoproteolytic activation and substrate hydrolysis
(Fig. 4B). These results imply that Taspase1 requires dimerization in
order to become sequentially activated: dimerization causes a reposi-
tioning of S291, which in turn triggers the autoproteolytic step of the
peptide bond between D233 and T234; the N-terminal T234 then
becomes the catalytic center; substrate binding displaces the inhibitory
chloride ion (Khan et al., 2005) and allows the repositioning of the T234
toﬁnally perform thenucleophilic attack at theD1–G1' peptide bond of a
substrate protein bound to the catalytic center.3.5. Establishment of the First Dominant-negative Taspase1 Variant
(dnTASP1)
Based on these experimental results, we created the double mutant
C163E/S291A. A S291A mutated monomer of Taspase1 is unable to
become hydrolyzed between D233 and T234 upon dimerization with
a wildtype Taspase1 monomer. Moreover, the C163E mutation within
the ‘docking head’ (see inset of Fig. 6) interferes with the movement
of E295 in the opposing monomer, and thus, blocks proper position-
ing of S291 in a co-bound wildtype Taspase1. Thus, binding of such a
double-mutant to wildtype Taspase1 should lead to enzymatically
inactive heterodimers, and substrate hydrolysis should not be observed.
To test this hypothesis, wildtype Taspase1 (Myc-tagged) and the
dnTASP1 (Flag-tagged) were co-transfected into HEK293T cells, and
subsequently, co-immunoprecipitation experiments were performed.
When mutant Taspase1 was precipitated and tested for co-bound
wildtype Taspase1 (Fig. 4A), we observed mainly inactive Taspase1
(amount of p50) when compared to autoproteolytically cleavedwildtype
Taspase1 dimers (amount of p22). In addition, no substrate cleavage
was observed (Fig. 4B). Thus, we concluded that the Ser291A/C163E
double mutant represents a dominant-negative mutant of Taspase1.
We termed this double-mutant dnTASP1.3.6. Functional Validation of Taspase1 Inhibition
dnTASP1 or wildtype Taspase1 expression plasmids were co-
transfected with an AF4–MLL expression vector into HEK293T cells.
Cellular lysates were tested for the presence of the AF4–MLL fusion pro-
tein. Full-length AF4–MLL (p328) is rapidly processed by Taspase1,
resulting in generation of p178N and p180C protein fragments.Western
blots were probed with the AF4·N antibody to detect the expected
p178N fragment, as published (Bursen et al., 2004). As shown in
Fig. 7A, the cleaved p178N protein fragment is visible in the presence
of wildtype Taspase1, while no p178N protein fragment could be
detected in the presence of dnTASP1. This is due to the fact that
uncleaved AF4–MLL fusion protein is a substrate of SIAH1 and SIAH2
(Bursen et al., 2004), that mediates a very rapid poly-ubiquitinylation
and proteasomal degradation of this oncoprotein. Only cleavage by
Taspase1 allows the formation of a stable AF4–MLL fusion protein com-
plex (Benedikt et al., 2011) that exerts the oncogenic properties
(Bursen et al., 2010). Any interference with the formation of this stable
complex leads to the rapid degradation of AF4–MLL (Pless et al., 2011).
In order to conﬁrm this independently, we established an
in vivo FRET biosensor assay that is based on BFP and GFP which
are separated by the Taspase1 cleavage sites CS1 (AEGQVD·GADD) or
CS2 (KISQLD·GVDD). This FRET biosensor was stably co-transfected
eitherwith empty vector (mock), wild-type Taspase1 (WT) or dnTASP1
(DN) into HEK293 cells. As shown in Fig. 7B, endogenous or transfected
Taspase1 was not able to quench the BFP protein, while dnTASP1 did.
The observed differences were highly signiﬁcant (p b 0.002) and clearly
demonstrated that in the presence of dnTASP1 normal Taspase1 activity
is diminished. This leaves the FRET biosensor uncleaved and a strong
quenching of BFP was the result (70% or 60% signal reduction at CS1
and CS2, respectively).
Next, we investigated the effects of dnTASP1 on HOXA gene
transcription (Fig. 7C). Distinct HOXA genes (HOXA7, HOXA9 and
HOXA10) are direct targets of the MLL protein complex. Expression
of dnTASP1 expression had only subtle effects on HOXA gene transcrip-
tion levels. However, HOXA1 gene transcription was slightly increased,
Fig. 7. Co-expression of FRET reporter or AF4–MLL with dnTASP1. A. Western blot experiments were performed after co-expression of AF4–MLL with wildtype Taspase1 or dnTASP1.
Detection of cleaved AF4–MLL fusion protein is shown on top. The presence of wildtype Taspase1 or dnTASP1 was conﬁrmed with an antiserum that detects the C-terminal Flag-Tag of
Taspase1 (p24) or of the uncleaved dnTASP1 mutant (p50). Protein loading controls were probed with an antiserum against β-actin. B. In vivo FRET assay. HEK293 cells were stably
transfected with the FRET biosensor in combination with empty vector (mock), wild-type Taspase1 (WT) or the dominant-negative Taspase1 mutant (DN). When Taspase cleavage
sites are cleaved then the energy transfer between BFP and GFP is not quenched. However if the cleavage sites are not cleaved by dnTASP1, quenching occurs which results in a lower
absorbance at 457 nm. C. Real-time PCR experiments performed for certainHOXA genes. Untransfected cells served as negative control. Several of the tested HOXA genes are differentially
expressed in the presence of dnTASP1.
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the presence of dnTASP1. These subtle effects are due to the fact that
Taspase1-unprocessed MLL protein is still able to steer transcription of
these target genes (Hsieh et al., 2003b). This is important because itFig. 8. Expression dnTASP1 in t(4;11) SEM cells. SEM cells were stably transfected with Sleepi
control) or the dnTASP1 in a doxycyclin-inducible manner. Transgenic cells were selected and
experiments were performed 8 days after induction to validate the expression of the inducible F
are displayed as X cells × 105 cells/ml. Cells expressing dnTASP1 (left panel) or LUC (right pan
SEM cells displayed a signiﬁcant difference in their cell numbers starting on day 6 (p-values are
where error bars overlapped at day 8. All experimentswere repeated in independent experimen
only indicated when applicable.demonstrates that knocking down endogenous Taspase1, and thus
also the functions of endogenousMLL, does not signiﬁcantly impair nor-
mal cell physiology. By contrast, interfering with functions provided by
Taspase1 in the context of the AF4–MLL oncoprotein leads to theng Beauty vectors (SBtet/GFP/Puro vectors) that either express Luciferase (LUC; negative
all experiments were performed with cells that uniformly express GFP. A. Western blot
lag-Tagged dnTASP1. B. Cell growth wasmeasured on days 0, 1, 2, 3, 6, 7 and 8. Cell counts
el) are displayed with and without induction by 1 μg/ml doxycyclin. DnTASP1-expressing
indicated for days 6, 7 and 8). This was not the case with Luciferase-expressing SEM cells,
ts (n=3).Mean values and standarddeviations of these 3 experiments are shown. SDwas
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thus, should have a dramatic effect for t(4;11) leukemia cells.
Finally, we stably transfected t(4;11)-positive SEM cells by using our
recently established Sleeping Beauty vector technology (Kowarz et al.,
2015). We used a control vector with cloned Luciferase, and another
vector with Flag-tagged dnTASP1. SEM cells were selected over
4 weeks to obtain two homogenous cell populations that all expressed
the GFP marker deriving from the vector backbone. Cells were then
seeded and induced for the expression of their transgenes (Fig. 8A).
The cell population of Luciferase-expressing SEM cells did not differ in
their growth behavior when compared to the non-induced control
(see Fig. 8B, right panel), but cells expressing dnTASP1 did show a
reproducible and signiﬁcant growth difference already after several
days. This was reproducible in three consecutive experiments (see
Fig. 8B, left panel). This was a ﬁrst indication, that dnTASP1 may indeed
impair functions deriving from the AF4–MLL fusion protein which then
resulted in impaired cell growth.We also analyzed the cell cycle of those
cells and observed a prolonged G0/1 phase after releasing from a
double-thymidine block (data not shown). This ﬁnding may explain
the observed effect on cell growth, but further studies will be necessary
to investigate these ﬁndings in more detail.
4. Discussion
In the context of t(4;11) leukemia, Taspase1 is a conditional
oncoprotein because it mediates the proteolysis of the AF4–MLL fusion
protein (p328). The resulting protein fragments (p178N and p180C)
form a heterodimer which resembles a molecular platform for the
assembly of the highly stable AF4–MLL multiprotein complex. This
high molecular weight complex exerts an enhanced P-TEFb activity
and causes ectopic histone signatures (Benedikt et al., 2011). Retro-
viral expression of the AF4–MLL fusion protein in murine hemato-
poietic stem/precursor cells caused the development of proB ALL in
mice (Bursen et al., 2010). Consequently, we decided to investigate
Taspase1 at the molecular level, aiming to understand the functional
relationship between Taspase1 and AF4–MLL, and to translate this
knowledge into novel strategies aiming to block the oncogenic func-
tions deriving from AF4–MLL.
First, we reﬁned the available crystal structure of human Taspase1
by in silicomodeling and used this structuralmodel of Taspase1 to iden-
tify critical amino acid residues. Based on our data, dimerization of two
Taspase1 monomers seems to be a key step for activating the intrinsic
autoproteolytic function (Fig. 6). There are several important amino
acids, but S291 and D233 are critical for the hydrolysis of the peptide
bond between residues D233 and T234. This is in line with recent ﬁnd-
ings obtained for several proteases, demonstrating that a single serine
residue is sufﬁcient to cause autoproteolytic activity (Polgár, 2005).
The T234 residue apparently remains in an inactive conformation due
to the presence of a chloride ion, which is coordinated by the peptide
backbone of G49, N100 and T234. This chloride anion functions as a
reversible competitive inhibitor at physiological chloride concentra-
tions (IC50 ~ 25 mM NaCl) (Khan et al., 2005). Binding of a cognate
substrate leads to the displacement of the inhibitory chloride anion,
possibly by using the carboxyl moiety of D4' deriving from the consen-
sus cleavage site (Q3[F,I,L,V]2D1|G1'X2'X3'D4'). As already described by
Khan et al. (2005) the displacement of the chloride ion allows T234 to
rotate by approximately 180° into the appropriate position to perform
the nucleophilic attack at the peptide bond between D1 and G1' of
bound substrate protein. This explains, why many efforts aiming to
identify a potent lead which targets the enzymatic center of Taspase1
remained so far without success.
In order to develop new drug strategies against Taspase1, we used
the approach tomutagenize Taspase1, and to use thesemutant variants
of Taspase1 in functional experiments. These experiments revealed
that inactive Taspase1 monomers use a ‘docking head’ to bind into
a ‘docking zone’ of an opposing Taspase1 monomer. This ‘dock-and-click’mechanism appears to be a prerequisite for the functional activa-
tion of Taspase1, because mutations within the docking head (W173A,
L146A/L165A, and L146A/H177A; I160E and C163E) or the correspond-
ing docking zone (R262A, E295A and R299E) abolished the pro- and
enzymatic activities of Taspase1.
The knowledge about Taspase1 and its particular activation
mechanism was subsequently used to design a dominant-negative
variant of Taspase1 (dnTASP1). This mutant combines the S291A
and C163E mutations. Therefore, such a mutant monomer — per se un-
able to become activated itself— binds with themodiﬁed docking head
to other Taspase1 monomers and thereby blocks the autoproteolytic
step. Co-immunoprecipitation and in vitro experiments revealed
that neither dnTASP1 homodimers nor dnTASP1::Taspase1 heterodi-
mers display any autoproteolytic or substrate hydrolysis activity
(Fig. 4AB).
DnTASP1 should represent per se a therapeutic protein in the context
of t(4;11) leukemia, because the co-expression of dnTASP1 together
with the leukemogenic AF4–MLL oncoprotein resulted in the disappear-
ance of the unprocessed AF4–MLL fusion protein (Fig. 7A). This is due to
the fact that unprocessed AF4–MLL fusion protein (p328) is a substrate
of the two E3-ligases SIAH1 and SIAH2. Both E3 ligases mediate
polyubiquitinylation, which in turn leads to a rapid proteasomal degra-
dation of the AF4–MLL oncoprotein (Bursen et al., 2004). By contrast,
Taspase1-hydrolyzedAF4–MLL (p178N andp180C) forms a heterodimer
which serves as a platform for the assembly of a high molecular weight
complex that is highly stable and leukemogenic (Benedikt et al., 2011).
We attempted to validate this hypothesis by analyzing the effects of
dnTASP1 on cells that bear a t(4;11) translocation. For this purpose,
we used our recently established Sleeping Beauty vectors to transfect
SEM cells (Kowarz et al., 2015). After a 4 week period of ‘pulsed
selection’ to obtain transgenic SEM cells, we analyzed the two trans-
genic cell populations for their growth behavior. The induction of the
dnTASP1 transgene led to a signiﬁcant and reproducible reduction of
cell growth in a doxycyclin-dependentmanner (Fig. 8), while control
experiments (Luciferase) did not reveal such effects. These data are
supporting our notion about the role of dnTASP1 for AF4–MLL.
Taspase1 is presumably not only important in the context of
normal MLL functions or leukemia, but also for solid tumors. Several
cell lines deriving from different solid tumors overexpress Taspase1
(Takeda et al., 2006). This suggests that Taspase1 has a potential func-
tion in tumor cells although only MLL germline alleles are expressed.
Solid tumors may require more cleaved MLL complexes e.g., to enhance
transcriptional processes. This important concept has been recently
successfully validated for breast cancer cells (Dong et al., 2014).
Several groups— including our own— have already tried to identify
potential Taspase1 inhibitors (Lee et al., 2009; Chen et al., 2012). How-
ever, all these screening strategies failed so far. The reason for this is not
quite clear but may be due to the inhibitory chloride anion that disables
Taspase1 in the absence of substrate. Conversely, our data imply to use
an allosteric inhibition approach in order to target Taspase1 by small
molecules. Taspase1 could potentially be inhibited by targeting the
‘docking zone’, e.g., by blocking the movement of the E295 residue.
However, such experiments would require to crystallize Taspase1
monomers (e.g., the W173A mutant). Since there is no guarantee
for good crystals, we suggest to use our established in vivo FRET reporter
assay for initial screening experiments. Since this cellular system may
respond to any kind of Taspase1 inhibition, it will presumably speed
up any kind of screening effort to identify ﬁrst lead structures.
In conclusion, we provide molecular evidence for a sequential
activation mode of Taspase1 upon dimerization. This process is based
on a ‘click-and-dock’ mechanism between Taspase1 monomers.
Mutations in the ‘docking head’ or ‘docking zone’ disable Taspase1
activities, indicating that Taspase1 can be inhibited by an allosteric
mechanism. This knowledge could be directly translated into efforts to
develop Taspase1 inhibitors by using the tools established throughout
this work.
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